Natera
Natera, Inc. is an American diagnostics company specializing in cell-free DNA testing and non-invasive genetic analytics. The company develops and commercializes molecular diagnostic services across women's health, oncology, and organ health, including non-invasive prenatal screening, carrier screening, liquid biopsy tumor tracking, and organ transplant rejection assessment. Its primary revenue drivers stem from reimbursement payments by commercial health insurers, government healthcare programs, and individual patients for diagnostic test volume processing. Natera holds a leading market position in non-invasive prenatal testing with its Panorama screen, while expanding footprint in oncology with its Signatera molecular residual disease test. The company primarily targets clinical healthcare providers, OB-GYNs, oncologists, and transplant centers in the United States. Corporate headquarters are situated in Austin, Texas, United States. Natera's common stock is listed on the Nasdaq Global Select Market.
46 of the funds FundTelligence covers report a position in Natera.
- Legal name
- Natera Inc.
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 46
- Exposure themes
- Diagnostics and screening, Genetic Testing, Maternal & Prenatal Health, Molecular Diagnostics, Precision Medicine & Genomics, Prenatal Testing, Prevention, Women's Health
Funds holding Natera
- JPM US Growth — JPM · 2.3 % (largest positions only, September 2026)
- Schroder ISF Global Equity Impact — Schroders · 2.09 % (full portfolio disclosed, June 2026)
- DNB Fund Women's Health — DNB · 2.05 % (full portfolio disclosed, August 2026)
- Handelsbanken Helse Tema — Handelsbanken · 1.98 % (full portfolio disclosed, October 2026)
- Nordea Global Consumer Trends — Nordea Funds · 1.84 % (full portfolio disclosed, September 2026)
- Franklin U.S. Opportunities Fund — Franklin Templeton · 1.81 % (full portfolio disclosed, September 2026)
- Franklin US Opportunities — Franklin Templeton · 1.81 % (full portfolio disclosed, September 2026)
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 1.64 % (full portfolio disclosed, October 2026)
Showing the 8 largest of 46 funds holding it.